Head of Business Development
Jack Elands
Phone: +44 7947 870 482
jack.elands@sidec.com
Research and development of monoclonal antibodies are hampered by inconclusive evidence of how a drug operates on a target. Conventional approaches often fall short of explaining the mode of action at a molecular level.
Revealing and exploring unique biological insight in antibody development guided by Sidec’s world class team and our proprietary Protein Tomography™ addresses this problem.
We provide our customers with exclusive biological information by visualizing and interpreting drug-target interaction events both in situ and in vitro.
Sidec provides competitive advantage and unique information in the development, protection and promotion of monoclonal antibodies and protein therapeutics.
Our unique offer enables our research partners to: